Loading...
•
Mar 31, 2023
Viking Therapeutics Q1 2023 Earnings Report
Announced financial results for the first quarter ended March 31, 2023, and provided a corporate update.
Key Takeaways
Viking Therapeutics reported a net loss of $19.5 million, or $0.25 per share, for the first quarter ended March 31, 2023. The company's research and development expenses were $11.0 million, while general and administrative expenses were $9.5 million. Viking ended the quarter with $135.7 million in cash, cash equivalents and short-term investments.
Completed enrollment in Phase 2b VOYAGE study of VK2809 for NASH and Fibrosis; data expected in 2Q 2023.
Reported VK2735 Phase 1 data demonstrating up to 6% Placebo-Adjusted Mean Weight Loss (7.8% from Baseline), promising safety and tolerability.
Initiated Phase 1 trial evaluating highly differentiated oral formulation of VK2735; results expected in 2H 2023.
Completed public offering of common stock raising gross proceeds of $287.5 Million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...